Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group

Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010.

(2020) Howard Safran et al.   JOURNAL OF CLINICAL ONCOLOGY

Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.

(2020) Ralf Dieter Hofheinz et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma

(2019) Patrick Sven Plum et al.   BMC CANCER

Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma

(2019) V Gambardella et al.   ANNALS OF ONCOLOGY

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

(2019) Anna Dorothea Wagner et al.   BMC CANCER

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

(2019) Salah-Eddin Al-Batran et al.   LANCET

Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study

(2019) Charlotte I. Stroes et al.   JOURNAL OF CLINICAL ONCOLOGY

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

(2018) Josep Tabernero et al.   LANCET ONCOLOGY

Perspectives of HER2-targeting in gastric and esophageal cancer

(2017) James N Gerson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

(2017) Peter C Thuss-Patience et al.   LANCET ONCOLOGY

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

(2016) Salah-Eddin Al-Batran et al.   LANCET ONCOLOGY

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

(2015) Joel Shapiro et al.   LANCET ONCOLOGY

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis

(2012) Y. Y. Janjigian et al.   ANNALS OF ONCOLOGY

Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial

(2012) A. F. C. Okines et al.   ANNALS OF ONCOLOGY

Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas

(2012) H. H. Yoon et al.   CLINICAL CANCER RESEARCH

Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment

(2011) Judith Maresch et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome

(2011) Maria D. Begnami et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET